Fibronectin (Fn) is produced by cells in blood vessels at inflammatory sites in vivo. Fn release into the circulation thus may be a marker for vascular injury. In support of this, we found that oxidant-induced vascular injury of isolated perfused rabbit lungs caused elevated circulating Fn levels. Western blot analysis indicated that Fn released from the injured blood vessels was intact, dimeric, and possessed electrophoretic mobility identical with Fn produced by fibroblasts. Unlike Fn isolated from rabbit plasma, Fn derived from lung perfusate or produced by fibroblasts reacted with antibodies raised to a synthetic peptide containing sequences from the extra type III Fn domain that is transcribed in fibroblasts but not hepatocytes. Vascular injury by protease was also associated with intravascular release of Fn, but with cleavage. Oxidant-induced vascular injury causes release of tissue-derived Fn, which can be distinguished from plasma Fn by its size and content of antigenic determinants of the extra type III domain.
Introduction
Oxidants accumulate at sites of tissue inflammation involving neutrophils (1) (2) (3) (4) . The ability ofantioxidants to block physiologic and morphologic disruption at these sites suggests that oxidants contribute to neutrophil-associated tissue injury (4) (5) (6) . Oxidants probably cooperate with other inflammatory effector agents, however, including proteases, to cause tissue injury in vivo (2, 3, 7, 8) . In order to test the effects of antioxidants and antiproteases in experimental animals and humans, effector-specific biochemical markers of tissue injury are needed. Ideally, these markers should be soluble and present in blood and/or other accessible body fluids. Fibronectins are large glycoproteins found in plasma, on cell surfaces, and in extracellular matrices. By binding other macromolecules as well as cells, they serve to promote anchorage of cells to substrata (9, 10) . Fibronectins are composed of subunits of variable primary structure (average molecular weight 250 kD), which are disulfide-linked to form dimers or multimers (9) (10) (11) (12) (13) . The predominant fibronectin in blood (plasma fibronectin) is secreted by hepatocytes, whereas cellular fibronectin is secreted by a variety of cultured cells including endothelial cells and fibroblasts (14) (15) (16) . Despite extensive physical and immunologic similarities, the two classes of fibronectin differ in electrophoretic behavior, solubility, and biologic activities (14, 17, 18) . Primary structural differences between plasma and cellular fibronectins have been found by peptide mapping (19) and immunologic techniques (20) . Recently, a difference region encoding for exactly one 90-amino acid type III structural repeat was identified in messenger (m)RNA from human fibroblasts and two human tumor cell lines, but could not be detected in human liver mRNA (13, 21, 22) . Since plasma fibronectin is synthesized by hepatocytes, it is likely that the extra type III repeat is a unique domain of cellular fibronectins (12, 21, 22) .
Fibronectin accumulates at sites ofinjury and inflammation in vivo (23) (24) (25) (26) (27) and is produced by cells in blood vessel walls at these sites (28) (29) (30) (31) . We therefore asked if cellular fibronectin might accumulate in the vascular compartment and in other fluids in communication with sites ofinflammatory tissue injury. We also asked if mediators of inflammatory tissue injury, including oxidants and proteases, could promote in situ release of cellularfibronectin. We chose to perform our studies in an in vitro perfused lung, since this model provides an abundantly vascular tissue that can be observed for both physiologic and biochemical changes under defined conditions.
Methods
Isolated perfused rabbit lung. Lungs from 2-to 2.5-kg New Zealand white rabbits were isolated and perfused as previously described (32) with the following modifications: a small animal ventilator (Harvard Instruments, Millis, MA) and a human coronary perfusion pump (Olson Medical Products, Ashland, MA) were used to provide ventilation and perfusion, respectively. 50 mg/kg ketamine (Parke-Davis Co., Morris Plains, NJ) and 10 mg/kg zylazine (Miles Laboratories, Shawnee, KA) were given intramuscularly as anesthesia for tracheotomy. After establishment of ventilation (15% 02, 5% C02, 80% N2, respiratory rate 20, tidal volume 10 ml/kg, positive end-expiratory pressure 1 cm H20), 32.5 mg/kg sodium pentobarbital (Western Medical Supply, Arcadia, CA) was given prior to thoracotomy. All In lungs injured by H202 infusion, no H202 accumulation could be detected in the circulation throughout 90 min of perfusion despite significant signs of vascular dysfunction. When lungs were removed from the perfusion circuit, however, H202 concentration increased linearly with time and was stable for 30 min following completion of infusion. Similarly, neither O-nor its immediate dismutation product H202 could be detected in the perfusate at any timepoint during experiments in which xanthine oxidase and purine (XO/P) were added to generate O2-intravascularly. After removal from the lung circulation, however, aliquots of perfusion fluid generated O-at rates commensurate with enzyme and substrate concentration. These findings were unaffected by the presence or absence of perfusate cells in the sample being assayed.
Protease injury. Beginning at 20 min, N-tosyl-L-phenylalanine chloromethyl ketone (TPCK)-treated trypsin (Sigma Chemical Co.) diluted in normal saline was constantly infused at 7.7 U/ml per min into the reservoir through the end ofthe 90-min recirculation. To analyze delivery of protease to the lung vasculature, samples of perfusate were assayed for trypsin activity by following the change in absorbance over time at 405 nm when samples or standards were incubated with the substrate N-benzoyl-L-phenylalanyl-L-valyl-L-arginine-p-nitro-anilide hydrochloride (Kabi Diagnostica, Stockholm, Sweden). Lungs infused with trypsin showed linear increases in perfusate trypsin activity over time. The average concentration of trypsin in perfusate changed linearly from 7±4 U/ml at 30 min (10 min after onset of infusion) to 356±35 U/ml at 90 min.
The doses of oxidants and trypsin used had been determined in preliminary experiments to produce significant increases in lung weight and lavage protein concentration compared with controls within a 90-min recirculation, consistent with vascular dysfunction. Preparation offluid samples. 2.5-ml samples of perfusion fluid were taken from the reservoir at 0, 30, 60, and 90 min. At the completion of each 90-min experiment, a narrow bore tube was quickly inserted into the right mainstem bronchus and the lower lobe was lavaged with 5 ml of ice-cold modified Gey's buffer-carbonate. The average volume recovered was 2.8 ml and did not differ significantly between experimental groups. Samples of perfusate and bronchoalveolar lavage (BAL) were Examination offibronectins by Western transfer. Electrophoresis was performed in low percentage or gradient SDS-polyacrylamide gels. The proteins in the gels were electrophoretically transferred to nitrocellulose sheets (Millipore Corp., Bedford, MA) (35) . After transfer, the sheets were blocked with 3% gelatin in Tris-buffered saline pH 7.4 (TBS) for 30 minutes and then soaked overnight in 1% gelatin in TBS containing goat antifibronectin antibodies. After washing in TBS containing 0.05% Tween 20, the sheets were soaked for 90 min in 1% gelatin in TBS containing HRP-conjugated swine antibodies to goat IgG. The sheets were washed prior to visualization of immunoreactive protein bands by incubation with 0.05% H202 and 0.5 mg/ml HRP Color Development Reagent (Bio-Rad Laboratories, Richmond, CA) in TBS containing 17% methanol for 30 min. Because the BSA in the perfusion buffer contained traces of bovine IgG with which the swine antibodies reacted, these antibodies were absorbed with bovine IgG (Calbiochem-Behring Corp.) immobilized on Sepharose beads prior to use in staining Western transfers in which samples of whole perfusate (rather than isolated fibronectins) were examined.
Isolation offibronectins. Fibronectin was purified from rabbit plasma, pooled lung perfusate, human plasma, fetal bovine serum, and conditioned media (Dulbecco's modified Eagle's medium containing 10% fibronectin-depleted fetal bovine serum) from confluent GM-1380 human fibroblasts and RAB-9 rabbit fibroblasts by affinity chromatography on gelatin Sepharose (36) .
To compare electrophoretic mobility ofFns contained in small samples of lung perfusate, lavage, and tissue, distortions in electrophoretic mobility due to other proteins was minimized by isolating fibronectin using small nonlimiting quantities of gelatin agarose beads (Pierce Chemical Co., Rockford, IL) (14) . 100 Ml of perfusate or lavage were shaken with 40 Ml ofpacked gelatin beads for 15 min at room temperature, pelleted by centrifugation, and washed three times with PBS containing 2 mM EDTA prior to elution with 100 ,d of sample buffer. Lung tissue fibronectin was isolated by first shaking -20 mg of lyophilized powder (2) from perfused (bloodless) rabbit lung tissue with 1 ml of 2 molar urea, 10 mg/ml porcine intestinal heparin (Sigma Chemical Co.), and 2 mM phenylmethylsulfonyl fluoride (PMSF) in PBS at room temperature for 4 h (37). The supernatant from the resulting suspension was diluted 10-fold with PBS and shaken with gelatin agarose beads prior to washing and elution with sample buffer.
Synthesis ofhumanfibronectin extra domain peptide. The 90 amino acid extra type III domain of human fibronectin contains a region occurring 36 to 60 amino acids from its amino terminal end in which there is a relative absence of sequence homology with other type III repeats (13) . The 19 amino acid peptide ELFPAPDGEEDTAELQGGC was therefore synthesized using solid phase methodology on peptide synthesizer (model 438, Applied Biosystems, Foster City, CA) (38). The Nterminal 17 amino acids of the peptide represent a region of the extra domain running 45 to 61 amino acids from its amino terminus. The carboxy terminal glycine and cysteine were added for linkage to the solid phase. The peptide migrated >90% in a single peak when subjected to high performance liquid chromatography using a C18 column (Vydac, Western Analytical Products, Temecula, CA). To confirm amino acid composition, the peptide was hydrolyzed in 6 N hydrochloric acid for 24 h at 1100C, dried overnight, and then applied to an amino acid analyzer column (Beckman 121-M, Beckman Instruments, Inc., Fullerton, CA). The individual amino acid contents conformed 99.9% with the desired peptide composition.
Antifibronectin antibodies. Antibodies to rabbit plasma fibronectin were raised in a goat by weekly multiple intradermal injections of 100 g ofpurified antigen emulsified in Freund's adjuvant (Difco Laboratories, Detroit, MI). Antibodies to the extra type III domain ofhuman fibronectin were similarly raised in goats by weekly intradermal injections in adjuvant of 150 ,ug of the extra domain peptide (ED peptide) coupled to keyhole limpet hemocyanin (Pacific Bio-Marine, Venice, CA) by the glutaraldehyde method (39) . Antibody titers specific for the ED peptide were checked by ELISA (40) .
To insure that the anti-ED peptide antibodies were in fact reactive with nonhepatic (cellular) but not hepatic (plasma) fibronectin, equal quantities of fibronectin purified from human plasma and GM-1380 cultured human fibroblast media (containing fibronectin-depleted fetal bovine serum) were subjected to SDS-PAGE with Western transfer. Protein concentrations were determined with BCA protein assay reagent (Pierce Chemical Co., Rockford, IL) using BSA as a standard. Staining was achieved with goat anti-ED peptide antibodies, goat anti-ED peptide antibodies preincubated with ED peptide, or goat anti-rabbit plasma fibronectin antibodies (crossreactive with human fibronectin). As seen in Fig. 1 , the anti-ED peptide antibodies did not react with fibronectin isolated from human plasma, but did react specifically with fibronectin isolated from human fibroblast conditioned media.
Measurement offibronectin in fluid samples. A quantitative noncompetitive ELISA was constructed using rabbit plasma fibronectin standards (41). Wells of microtiter plates were first coated with goat antirabbit plasma fibronectin antibodies immunopurified as described (11) and diluted in 0.1 M NaHCO3. Next, standards and samples, both diluted in perfusion buffer (2% BSA) were applied. Finally, immunopurified goat antirabbit plasma fibronectin antibodies conjugated to alkaline phosphatase (from bovine intestinal mucosa; Sigma Chemical Co.) with glutaraldehyde (41) In contrast to the oxidant injury model, continuous trypsin infusion caused edema formation between 60 and 90 min (40- 70 min after onset ofinfusion). Perfusate fibronectin levels measured by ELISA decreased throughout the trypsin infusion, including the period of edema formation (Fig. 2) .
Fibronectin retrieved by lavage of the alveolar space at 90 min was elevated in oxidant-treated groups compared with controls. Catalase pretreatment of perfusion fluid prior to addition of oxidants prevented the increase in BAL fibronectin associated with oxidant exposure (Table I) (Fig. 3 A) . Under reducing conditions the subunits of perfusate fibronectin showed similar electrophoretic mobility to subunits of fibronectin extracted from normal rabbit lung tissue (Fig. 3 B) . Both migrated as single bands (-260 kD) in conventional low percentage gels. These bands were of a higher apparent molecular weight than either of the bands formed by the subunits of rabbit plasma fibronectin (210 and 240 kD). Rabbit plasma fibronectin diluted in perfusion buffer and subjected to 2 mM H202 for 90 min showed no change in electrophoretic behavior (not shown). In order to resolve small differences in electrophoretic mobility between subunits, samples of fibronectin were also subjected to prolonged electrophoresis under reducing conditions. Duration of electrophoresis was calibrated by the position ofprestained molecular weight standards (Bethesda Research Laboratories, Bethesda, MD). Under these conditions, the subunits of perfusate fibronectin resolved into a doublet possessing electrophoretic mobility identical with that of fibronectin isolated from the media of rabbit fibroblasts which had been grown in fibronectin-depleted media (see Methods) (Fig. 3 C) . Treatment of the lung vasculature with either O2-or H202 caused intravascular release of fibronectin of similar subunit composition.
Fibronectin in the perfusion fluid ofall trypsin-treated lungs was progressively cleaved over time. As shown in Fig. 4 , the (Fig. 5) . Antibodies to the ED peptide also specifically stained higher molecular weight subunits of the intact fibronectin that accumulated at low levels in perfusion fluid of uninjured lungs (not shown).
Electrophoretic examination of rabbit fibroblast fibronectin using anti-extra domain antibodies. Cellular fibronectin isolated from rabbit fibroblast media was heterodimeric with two major subunit populations that comigrated with those of rabbit lung perfusate fibronectin. Like perfusate fibronectin, only the slower migrating subunit population stained with anti-ED antibodies (Fig. 6 ).
Effects of oxidant or protease treatment on parameters of lung vascularfunction. All lungs subjected to the cited doses of injurious agents were observed for 90 min of recirculation and ventilation. Net increase in lung weight over this period and BAL protein concentration were significantly increased in lungs treated with oxidants or protease compared with controls (Table  II) . Increase in pulmonary artery pressure (PAP) over baseline was also greater in the oxidant and protease-treated groups than bronectin from the media (con- 1 2 taining fibronectin-depleted fetal bovine serum) of confluent rabbit fibroblasts was accomplished by mixing 100 M1 of packed gelatin agarose beads with 4 ml of media followed by elution with 100 ul of sample buffer. To examine the possibility that fibronectin detected in fibroblast media might represent a mixture of rabbit cellular fibronectin and residual bovine fibronectin, 4 ml of media not previously exposed to fibroblasts was subjected to affinity-isolation as described above. In lane 5. 30 Mi of the resulting eluate was subjected to electrophoresis and Western transfer with staining by antiplasma fibronectin antibodies (identical conditions as lanes 2 and 4). tion uniformly revealed that the predominant protein band comigrated with the BSA in the perfusion fluid (not shown).
Cellular composition ofperusate and lung tissue. In all experiments, the majority of nonerythrocytic cells identified by hemocytometer in perfusion fluid samples were mononuclear with large round nuclei. Wright-stained smears of these cells revealed that they possessed granular cytoplasm and were similar in size to polymorphonuclear leukocytes also detected in per- Intact fibronectin dimers are released into blood vessels of isolated perfused rabbit lungs in response to levels ofcirculating oxidants that lie within the consumptive capabilities of lung antioxidant defenses. These levels of oxidants nevertheless cause vascular dysfunction (evident as lung weight gain), and this process correlates temporally with fibronectin release. When subjected to electrophoresis, subunits of the released fibronectin migrate more slowly than those of rabbit plasma fibronectin. This is typical of human, chicken, rat, and hamster cellular fibronectins in comparison with their plasma counterparts (14, 17, 43) . Additionally, the released fibronectin shows similar electrophoretic mobility to fibronectin extracted from normal rabbit lung tissue perfused free of blood elements. Finally, the perfusion fluid fibronectin possesses electrophoretic mobility which is identical with rabbit fibroblast-derived cellular fibronectin. Therefore, the fibronectin released by the oxidant-injured vasculature of the in vitro perfused lung appears by electrophoretic comparisons to be cellular fibronectin.
To confirm the designation of perfusate fibronectin as cellular fibronectin we exploited the known differences in primary structure between non-hepatic (cellular) and hepatic (plasma) fibronectins (13 (44, 45) have been shown to synthesize fibronectin, differences in perfusate concentrations of fibronectin between oxidant and control groups could conceivably arise from differences in cellular composition of perfusate or tissue. However, significant differences in circulating cells were not apparent between these groups. Nor were there discernible differences in tissue cellularity as judged by light microscopy. Endothelial cells, the major cell group in contact with the circulation in our model, secrete intact cellular fibronectin dimers into cell culture medium when grown in tissue culture (15, 16) . Additionally, these cells have been shown to produce fibronectin in response to tissue injury and inflammation in vivo (28) (29) (30) (31) . These facts, taken together with our data, suggest that endothelial cells are a potential site of release offibronectin in response to oxidant stress.
In contrast to the results obtained with oxidants, proteaseinduced vascular injury ofthe perfused lung was associated with decreased levels of circulating fibronectin measured by immunoassay (ELISA). However, Western blotting revealed that the samples subjected to ELISA did not contain intact fibronectin. Whereas perfusate samples taken prior to addition of protease contained fibronectin with electrophoretic mobility consistent with intact cellular fibronectiin, samples at later time points contained fibronectin that had been proteolytically degraded. Since proteolysis was shown to lead to decreased measured values by ELISA, fibronectin may have been proteolytically released from vessels, but not detected by immunoassay due to diminished antigenicity.
The increased fibronectin levels in the lavage fluids from lungs with signs of vascular dysfunction (increased lung weight and lavage protein) could reflect movement of fluid and proteins from the circulation into the alveoli and/or local release of fibronectin from alveolar tissue or cells. Since the predominant protein that was detected in the airspaces ofinjured lungs comigrated with perfusion fluid BSA in SDS-PAGE, it is likely that fluid and proteins, including fibronectin, moved from the circulation to airspaces during vascular injury in this model.
The association of oxidant exposure with intravascular release of cellular fibronectin in the in vitro perfused rabbit lung raises the possibility that cellular fibronectin could represent a soluble marker in blood or other accessible tissue fluids for oxidant-induced injury. Total plasma fibronectin levels have been noted to increase in rats during experimental systemic inflammatory joint disease (46) and during exposure to hyperoxia (47) . Because leukocyte-associated inflammation and hyperoxia both involve generation of oxidants at sites of tissue injury (1-6, 48, 49) , the associated accumulation of circulating fibronectin in these models could in part reflect, as in our models, release of fibronectin by oxidant-injured vasculature. Accumulation of such cellular fibronectin in the plasma of intact animals would not be expected to reflect injury to any specific organ, since cells (endothelial cells, fibroblasts, etc.) that produce cellular fibronectin are ubiquitous. However, detection of cellular fibronectin in organ-specific fluid (BAL, synovial fluid, Urine) could potentially point to local organ injury. For example, in recent experiments we have caused oxidant-induced injury of lung tissue in intact rabbits by instillation of glucose oxidase and glucose (GO/G) into the lower airways. This has uniformly (in seven of seven rabbits) led to histologic evidence of injury to the pulmonary parenchyma (including focal disruption of alveolar structure as well as hemorrhage) 4 h posttreatment. Instillation of catalase with the GO/G has uniformly prevented histologic signs ofinjury (6 out of6 rabbits), indicating that H202 produced by the GO/G is necessary for injury to occur. Using Western blot analysis, we have detected intact cellular fibronectin in the BAL of all of the rabbits treated with GO/G but none of the rabbits treated with GO/G plus catalase. The ED-containing fibronectin subunits in the BAL of the rabbits with pulmonary tissue injury caused by GO/G comigrate during electrophoresis with the slower migrating subunits of the cellular fibronectin in perfusate ofisolated rabbit lungs injured by oxidants as described in the present study (Peters and Cochrane, manuscript in preparation). This result also confirms the capacity of oxidants to trigger the appearance of cellular fibronectin in body fluids not limited to in vitro perfused organ systems.
In summary, in this study we have shown that oxidant and protease-induced vascular injury are each associated with characteristic alterations in fibronectin derived from nonhepatic tissue in vitro. Nonhepatic tissue fibronectin (cellular fibronectin) is therefore recognized as an in situ target of these two major classes of inflammatory effector agents. Additionally, we have described a method for the assay of tissue fibronectin to the exclusion of plasma fibronectin. Thus, the use of tissue fibronectin as a probe for effector-specific tissue injury in vivo is now feasible.
